Introduction
============

In 2009, the Meta-Analysis of New Generation Antidepressants Study[@b2-ndt-13-117] reported that clinically important differences for both efficacy and acceptability exist among commonly prescribed antidepressants in favor of escitalopram and sertraline. In 2012, escitalopram was demonstrated to have the highest probability of remission and is the most effective and cost-effective pharmacological treatment in a primary care setting.[@b3-ndt-13-117] Escitalopram appears to be the best first-line antidepressant for treating major depressive disorder (MDD). In contrast, in 2010, paroxetine immediate release was the best-selling antidepressant in Japan.[@b4-ndt-13-117]

There were three randomized trials of escitalopram versus paroxetine immediate release in patients with MDD. Boulenger et al's study and Kasper et al's study reported that escitalopram is more effective and safer than paroxetine immediate release in the long-term treatment of patients with MDD.[@b5-ndt-13-117],[@b6-ndt-13-117] Baldwin et al reported that significantly (*P*\<0.01) more paroxetine immediate release was associated with a higher discontinuation rate compared with escitalopram.[@b7-ndt-13-117] As the National Institute for Health and Care Excellence guidelines indicated, a higher incidence of discontinuation symptoms is observed for paroxetine immediate release than for other selective serotonin reuptake inhibitors (SSRIs).[@b8-ndt-13-117] In order to overcome these drawbacks of paroxetine immediate release, paroxetine controlled release was developed in Japan in 2012 to improve general tolerability, particularly, gastrointestinal tolerability. Although there are no published data which demonstrate that paroxetine controlled release has a lower risk for producing discontinuation effects than paroxetine immediate release, one randomized trial showed that paroxetine controlled release is associated with low rates of early-onset nausea and dropout rates due to adverse events, which were comparable to those of placebo.[@b9-ndt-13-117] However, there are no direct comparisons between escitalopram and paroxetine controlled release in patients with MDD. Therefore, we conducted a 24-week, rater-masked, randomized trial of escitalopram versus paroxetine controlled release in Japanese patients with MDD.

Methods
=======

Subjects
--------

This study was conducted from July 2013 to December 2015 at the Fujita Health University Hospital, Jindai Clinic, Jindai Hospital, Toyota Memorial Hospital, Holy Cross Hospital, and Okehazama Hospital. The trial was registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN000011191). Patients were diagnosed according to the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text Revision criteria by the consensus of at least two experienced psychiatrists on the basis of structured interviews conducted using the Mini-International Neuropsychiatric Interview and a review of all medical records. All subjects met the following inclusion criteria: 1) age 20--70 years; 2) a 17-item Hamilton Rating Scale for Depression (HAMD-17),[@b1-ndt-13-117] with total score at baseline being ≥20; 3) no neurologic or systemic diseases, including disturbance of hematopoiesis; 4) no history of electroconvulsive therapy within 6 months before enrollment; 5) absence of pregnancy; and 6) no dependence on any addictive substances other than nicotine in the past 5 years before enrollment. All subjects underwent laboratory blood testing and electrocardiography at the time of enrollment, and no patients were excluded because of a medical condition.

The clinical trial was described in detail, and written informed consent was obtained from all participants and their guardians. This study was approved by the six ethics committees of the Fujita Health University Hospital, Jindai Clinic, Jindai Hospital, Toyota Memorial Hospital, Holy Cross Hospital, and Okehazama Hospital.

Procedures
----------

All patients were randomly assigned to one of the two treatment groups by the central registration office. When the patients satisfied the inclusion and exclusion criteria for this multicenter trial, the randomization procedure was conducted by the authors in contact with a central registration office by telephone. The authors generated an allocation schedule before the start of the study using a random number table. The initial starting dose of escitalopram was 5--10 mg/day, with dose increases when needed in increments of 5--10 mg/day to a maximum of 20 mg/day. The initial starting dose of the paroxetine controlled release was 12.5 mg/day, with a dose increase of 12.5--50 mg/day. The subsequent antidepressant dosage was increased or decreased according to the patient's tolerance and therapeutic response. Lorazepam was used as an anxiolytic, and the hypnotics brotizolam and eszopiclone were permitted during our clinical trial (by prescription and for valid clinical reasons).

Evaluation of psychopathology, tolerability, and safety
-------------------------------------------------------

The 21-item HAMD (HAMD-21)[@b1-ndt-13-117] was completed at baseline and at 2, 4, 8, 12, and 24 weeks after starting administration or at discontinuation. Treatment-emergent adverse events were recorded at each time point, including immediately before the study, upon spontaneous complaints and through clinical observation using the Udvalg for Kliniske Undersogelser Side Effect Rating Scale.[@b10-ndt-13-117]

The raters who administered the psychometric tests were masked to the treatment group allocation, but the patients and physicians were aware of the treatment that was received. Raters consisted of psychologists who were not involved in any treatment decisions or the evaluation of side effects. Therefore, they were not required to know the pharmacologic treatment. The following measures were taken to maintain the masking of the raters. Electronic data from the trial were password protected, all case report forms were securely stored, and discussions about patients among the research teams were restricted. Moreover, the participants were reminded to avoid open discussion of the treatment assignment with the raters.

The primary outcome measure was the improvement of the HAMD-21 total scores at week 24. The secondary outcomes included: the HAMD-21 scores at 2, 4, 8, and 12 weeks; the HAMD-17 scores at 2, 4, 8, 12, and 24 weeks; the response rate at 2, 4, 8, 12, and 24 weeks (clinical response defined as ≥50% reduction in the HAMD-17 or -21 total score from baseline to endpoint); the remission rate at 2, 4, 8, 12, and 24 weeks (clinical remission defined as the HAMD-17 total score ≤6 or HAMD-21 total score ≤7);[@b11-ndt-13-117] the discontinuation rate; and individual adverse events.

Statistical analysis
--------------------

Modified intent-to-treat analysis was performed using the last observation carried forward method. Baseline continuous and categorical variables were compared between the treatment groups by an independent *t*-test and a chi-square test, respectively. Paired Student's *t*-tests were used to assess the changes in the HAMD-21 and HAMD-17 total scores from the baseline to endpoint. The comparison between the escitalopram and paroxetine controlled-release treatment groups was made by determining the change in the HAMD-21 (or HAMD-17) total score at the endpoint (2, 4, 8, 12, and 24 weeks) from baseline, based on an analysis of covariance model using the baseline HAMD-21 (or HAMD-17) score as covariates. We also used multiple logistic regression analyses to examine which antidepressant was associated with a higher response rate or remission rate (dependent variable: response rate \[HAMD-21 or HAMD-17\] or remission rate \[HAMD-21 or HAMD-17\]; independent variable: treatment group; and covariates: baseline HAMD-21 or HAMD-17 score, respectively). A Kaplan--Meier analysis was used to estimate the time to discontinuation for the two treatment groups, and the results were compared using a log-rank test. We also compared the change in body weight from baseline to endpoint between the escitalopram and paroxetine controlled-release treatment groups based on an analysis of covariance model using the baseline value as a covariate. Incidences of individual adverse events during the study were compared between the treatment groups using a chi-square test. The final dose of antidepressants was evaluated based on the fluoxetine equivalent.[@b12-ndt-13-117] The statistical power regarding the primary outcome for efficacy was also calculated (alpha =0.5, <http://www.biostat.ucsf.edu/sampsize.html>).

Statistical analyses were performed using Statistical Package for the Social Sciences Statistics for Windows (Version 22.0; Corporation, Armonk, NY, USA) and JMP (JMP 12.2. 1J; SAS Japan Inc., Tokyo, Japan). A *P*-value of \<0.05 was considered statistically significant for all tests.

Results
=======

The demographics and other characteristics of the patients are presented in [Table 1](#t1-ndt-13-117){ref-type="table"}. A total of 88 patients were recruited, all of whom were diagnosed with MDD at enrollment. Of these, 77.3% were first-episode patients and 61.4% were male, and the mean age was 40.8±13.4 years. There were no significant differences in most variables between the treatment groups ([Table 1](#t1-ndt-13-117){ref-type="table"}).

The discontinuation rate was 58.0% (escitalopram, 55.8% and paroxetine controlled release, 60.0%; [Table 2](#t2-ndt-13-117){ref-type="table"}). There was no significant difference in the mean times to discontinuation between the escitalopram and paroxetine controlled-release treatment groups (13.4±10.1 vs 13.2±9.92 weeks; *χ*^2^~(1)~=0.0836, *P*=0.773). All 88 patients were included in the efficacy and safety analyses. The mean escitalopram and paroxetine controlled-release doses at endpoint were 13.6±5.81 mg/day (fluoxetine equivalent, 30.2±12.9 mg/day) and 24.8±13.3 mg/day (fluoxetine equivalent, 29.2±15.7 mg/day), respectively (*t*~(1)~=0.0836, *P*=0.773).

Both escitalopram and paroxetine controlled-release treatments were associated with significant improvements in the HAMD-21 and HAMD-17 total scores at 2, 4, 8, 12, and 24 weeks ([Table S1](#SD1-ndt-13-117){ref-type="supplementary-material"}). However, there were no significant differences in the magnitude of the HAMD-21, and HAMD-17 total score decreases at any time between the escitalopram and paroxetine controlled-release treatment groups ([Table 3](#t3-ndt-13-117){ref-type="table"}). The statistical power with respect to the primary outcome was 43%. Also, there were no significant differences in the response rate at any time point between the treatment groups ([Figures 1](#f1-ndt-13-117){ref-type="fig"} and [2](#f2-ndt-13-117){ref-type="fig"}).

No patients had serious adverse events such as death, suicide attempt, and serotonin syndrome, and there were no significant differences in the incidence of individual adverse events between the groups ([Table 4](#t4-ndt-13-117){ref-type="table"}). Moreover, there were no significant differences in body weight at the endpoint between the treatment groups ([Table 4](#t4-ndt-13-117){ref-type="table"}).

Discussion
==========

This is the first randomized trial involving a comparison between escitalopram and paroxetine controlled release in Japanese patients with MDD. There were no significant differences in the efficacy and safety outcomes between the escitalopram and paroxetine controlled-release treatment groups in this study. However, our study found that discontinuation rates due to adverse events in both treatment groups were relatively high compared with other studies on SSRIs.[@b13-ndt-13-117] In a recent network meta-analysis, escitalopram emerged as the most efficacious agent among the SSRIs and was the best tolerated of the new-generation antidepressants (eg, agomelatine, duloxetine, escitalopram, fluvoxamine, fluoxetine, mirtazapine, paroxetine, sertraline, trazodone, and venlafaxine) that were analyzed.[@b13-ndt-13-117] We did not find significant differences in any efficacy outcome between the escitalopram and paroxetine controlled-release treatment groups in this study. The statistical power with respect to the primary outcome was 43%. Therefore, our results might be a statistical error due to an insufficient sample size.

Limitations
===========

One of the primary limitations of this study is that this study was not double blinded. The physicians responsible for assessing the adverse events were aware of which treatment was received by which patient. Although the raters were masked to the nature of the antidepressant treatment and were not involved in any side effect ratings or management decisions, it is possible that they were inadvertently informed of the group allocation by the patients. The second limitation is that this study did not include a placebo arm. The third limitation is the small sample size, particularly in the subgroup analysis (the statistical power with respect to the primary outcome was 43%). Therefore, we did not perform an HAMD item analysis. The fourth limitation is that we did not correct for multiple comparisons (eg, using Bonferroni's correction), because the application of a more stringent alpha level for secondary outcomes would have been too conservative in this small sample.[@b14-ndt-13-117],[@b15-ndt-13-117] The fifth one is that we did not count the number of patients who were screened for entry in the study. Finally, the intent-to-treat analysis using the last observation carried forward method may have influenced the results. The discontinuation rate was high, and thus, this method may yield a biased estimate of the treatment effect and underestimate the variability of the results.[@b16-ndt-13-117] It is not clearly justified why this analysis, in particular, is appropriate and valid. However, if we had selected a complete analysis, our sample size would have been too small.

Conclusion
==========

In conclusion, our findings suggest that although escitalopram and paroxetine controlled release are effective in patients with MDD, discontinuation rates due to adverse events in both treatment groups were relatively high. However, because our study might be underpowered to detect significant differences in efficacy and safety outcomes between the escitalopram and paroxetine controlled-release treatment groups, further study using a larger sample size is required.

Supplementary material
======================

###### 

Endpoint change in Hamilton Depression Rating Scale scores at 2, 4, 8, 12, and 24 weeks from the baseline

  Mean score at baseline                                                            Mean score at 2 weeks   *t~df~*, *P*-value        Mean score at 4 weeks   *t~df~*, *P*-value        Mean score at 8 weeks   *t~df~*, *P*-value        Mean score at 12 weeks   *t~df~*, *P*-value        Mean score at 24 weeks   *t~df~*, *P*-value
  --------------------------------------------------------------------------------- ----------------------- ------------------------- ----------------------- ------------------------- ----------------------- ------------------------- ------------------------ ------------------------- ------------------------ -------------------------
  Hamilton Depression Rating Scale-17 total score: escitalopram                                                                                                                                                                                                                                                       
  23.7±3.58                                                                         14.3±5.97               *t*~42~=−9.38, \<0.0001   11.7±6.37               *t*~42~=−11.2, \<0.0001   10.9±6.71               *t*~42~=−11.4, \<0.0001   10.3±7.00                *t*~42~=−11.6, \<0.0001   9.23±7.24                *t*~42~=−12.3, \<0.0001
  Hamilton Depression Rating Scale-17 total scores: paroxetine controlled release                                                                                                                                                                                                                                     
  23.2±3.78                                                                         16.1±7.09               *t*~44~=−6.57, \<0.0001   13.6±7.63               *t*~44~=−8.28, \<0.0001   12.3±7.64               *t*~44~=−9.61, \<0.0001   12.6±7.67                *t*~44~=−9.03, \<0.0001   11.4±7.86                *t*~44~=−9.72, \<0.0001
  Hamilton Depression Rating Scale-21 total scores: escitalopram                                                                                                                                                                                                                                                      
  25.8±4.24                                                                         15.7±6.53               *t*~42~=−9.15, \<0.0001   13.2±7.41               *t*~42~=−10.3, \<0.0001   12.0±7.58               *t*~42~=−11.3, \<0.0001   10.4±7.76                *t*~42~=−13.0, \<0.0001   10.1±7.97                *t*~42~=−12.6, \<0.0001
  Hamilton Depression Rating Scale-21 total scores: paroxetine controlled release                                                                                                                                                                                                                                     
  25.1±4.71                                                                         17.4±8.25               *t*~44~=−6.50, \<0.0001   14.8±8.82               *t*~44~=−8.00, \<0.0001   13.1±8.79               *t*~44~=−9.55, \<0.0001   13.1±9.27                *t*~44~=−8.95, \<0.0001   11.6±9.62                *t*~44~=−9.61, \<0.0001

**Note:** Data presented as mean ± standard deviation.

**Abbreviation:** *df*, degrees of freedom.
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###### 

Baseline characteristics of the patients

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                      Escitalopram\   Paroxetine controlled release (n=45)   Group difference\           *P*-value
                                                                                (n=43)                                                 (*χ*^2^ test or *t*-test)   
  ----------------------------------------------------------------------------- --------------- -------------------------------------- --------------------------- -----------
  Male (%)                                                                      25 (58.1)       29 (64.4)                              *χ*^2^=0.369                0.544

  Age, years (mean ± SD)                                                        38.9±12.4       42.5±14.2                              *t*=−1.28                   0.205

  First episode (%)                                                             35 (81.4)       33 (73.3)                              *χ*^2^=0.819                0.366

  Educational history, years (mean ± SD)                                        14.0±1.88       13.6±2.22                              *t*=−0.752                  0.454

  Hospitalization (%)                                                           0 (0.00)        1 (2.22)                               *χ*^2^=1.35                 0.245

  Study center (FHU hospital, %)                                                19 (44.2)       26 (57.8)                              *χ*^2^=1.63                 0.202

  Married (%)                                                                   25 (58.1)       19 (42.2)                              *χ*^2^=2.24                 0.135

  Unemployed (%)                                                                8 (18.6)        12 (26.7)                              *χ*^2^=0.819                0.366

  Current smoker (%)                                                            9 (20.9)        9 (20.0)                               *χ*^2^=0.012                0.914

  Hamilton Depression Rating Scale-17 total scores (mean ± SD)                  23.7±3.58       23.2±3.78                              *t*=−0.605                  0.547

  Hamilton Depression Rating Scale-21 total scores (mean ± SD)                  25.8±4.24       25.1±4.71                              *t*=−0.710                  0.480

  Comorbid psychiatric illness (%)[\*](#tfn1-ndt-13-117){ref-type="table-fn"}   6 (14.0)        6 (13.3)                               *χ*^2^=0.007                0.933

  Body weight, kg (mean ± SD)                                                   65.0±13.9       65.7±12.3                              *t*=0.240                   0.811

  Use of antidepressant (%)                                                     0 (0.00)        0 (0.00)                               Not applicable              

  Use of hypnotic (%)                                                           6 (14.0)        6 (13.3)                               *χ*^2^=0.007                0.933

  Use of anxiolytic (%)                                                         0 (0.00)        1 (2.22)                               *χ*^2^=1.35                 0.245
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Generalized anxiety disorder and/or panic disorder.

**Abbreviations:** FHU, Fujita Health University; SD, standard deviation.

###### 

Discontinuation rate

  Number of patients                   Escitalopram   Paroxetine controlled release
  ------------------------------------ -------------- -------------------------------
  Randomized                           43             45
  Completed the trial (%)              19 (44.2)      18 (40.0)
  Discontinued the trial (%)           24 (55.8)      27 (60.0)
  **The reasons of discontinuation**                  
  Inefficacy (%)                       9 (20.9)       8 (17.8)
  Adverse events (%)                   8 (18.6)       11 (24.4)
  Other reasons (%)                    7 (16.2)       8 (17.8)

###### 

Group difference in Hamilton Depression Rating Scale scores at 2, 4, 8, 12, and 24 weeks

                                                         Baseline score   Change in score at 2 weeks   *F~df~*, *P*-value      Change in score at 4 weeks   *F~df~*, *P*-value      Change in score at 8 weeks   *F~df~*, *P*-value       Change in score at 12 weeks   *F~df~*, *P*-value      Change in score at 24 weeks   *F~df~*, *P*-value
  ------------------------------------------------------ ---------------- ---------------------------- ----------------------- ---------------------------- ----------------------- ---------------------------- ------------------------ ----------------------------- ----------------------- ----------------------------- -----------------------
  **Hamilton Depression Rating Scale-17 total scores**                                                                                                                                                                                                                                                                        
  Escitalopram                                           23.7±3.58        −9.40±6.57                   *F*~1.86~=2.00, 0.161   −12.0±7.01                   *F*~1.86~=1.92, 0.169   −12.8±7.36                   *F*~1.86~=1.03, 0.314    −13.4±7.56                    *F*~1.86~=2.58, 0.112   −14.5±7.73                    *F*~1.86~=3.10, 0.082
  Paroxetine controlled release                          23.2±3.78        −7.11±7.26                                           −9.58±7.76                                           −10.9±7.62                                            −10.6±7.86                                            −11.4±7.84                    
  **Hamilton Depression Rating Scale-21 total scores**                                                                                                                                                                                                                                                                        
  Escitalopram                                           25.8±4.24        −10.0±7.18                   *F*~1.86~=1.62, 0.206   −12.6±8.01                   *F*~1.86~=1.25, 0.267   −13.8±8.01                   *F*~1.86~=0.775, 0.381   −15.3±7.75                    *F*~1.86~=3.07, 0.084   −15.6±8.16                    *F*~1.86~=1.02, 0.315
  Paroxetine controlled release                          25.1±4.71        −7.69±7.93                                           −10.3±8.63                                           −12.0±8.42                                            −12.0±8.98                                            −13.4±9.38                    

**Notes:** Covariate: Hamilton Depression Rating Scale score at baseline. Data presented as mean ± standard deviation.

**Abbreviation:** *df*, degrees of freedom.

###### 

Adverse events observed in the study (incidence ≥5%)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Individual adverse events                                            Escitalopram\   Paroxetine controlled release (n=45)   Group difference (*χ*^2^ test or analysis of covariance and *P*-value
                                                                       (n=43)                                                 
  -------------------------------------------------------------------- --------------- -------------------------------------- -----------------------------------------------------------------------
  At least one adverse event (%)                                       26 (60.5)       29 (64.4)                              *χ*^2^=0.149 and 0.700

  Headache (%)                                                         5 (11.6)        2 (4.44)                               *χ*^2^=1.59 and 0.207

  Somnolence (%)                                                       12 (27.9)       8 (17.8)                               *χ*^2^=1.29 and 0.256

  Dizziness (%)                                                        6 (14.0)        4 (8.89)                               *χ*^2^=0.562 and 0.453

  Anxiety (%)                                                          9 (20.9)        4 (8.89)                               *χ*^2^=2.58 and 0.108

  Insomnia (%)                                                         6 (14.0)        5 (11.1)                               *χ*^2^=0.162 and 0.687

  Decreased salivation (%)                                             3 (6.98)        5 (11.1)                               *χ*^2^=0.460 and 0.498

  Nausea/vomiting (%)                                                  11 (25.6)       12 (26.7)                              *χ*^2^=0.013 and 0.908

  Diarrhea (%)                                                         9 (20.9)        6 (13.3)                               *χ*^2^=0.901 and 0.342

  Constipation (%)                                                     6 (14.0)        3 (6.67)                               *χ*^2^=1.29 and 0.256

  Loss of sexual desire (%)                                            2 (4.65)        3 (6.67)                               *χ*^2^=0.168 and 0.682

  Use of hypnotic (%)                                                  6 (14.0)        6 (13.3)                               *χ*^2^=0.007 and 0.933

  Use of anxiolytic (%)                                                0 (0.00)        1 (2.22)                               *χ*^2^=1.35 and 0.245

  Weight gain (%)                                                      1 (2.33)        3 (6.67)                               *χ*^2^=1.00 and 0.317

  Mean weight change (kg)[\*](#tfn5-ndt-13-117){ref-type="table-fn"}   0.853±3.05      0.502±2.11                             *F*~1.86~ =0.471 and 0.494
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Covariate: body weight at baseline. Data presented as mean ± standard deviation.
